Clinical Research Directory

Inclusion Criteria: 1. Age12 years or older, any gender; 2. Signed"Informed Consent Form"; 3. Clinically diagnosed with non-segmental vitiligo; 4. Vitiligo area less than 10% of body surface area; 5. Agreed to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit; 6. Female subjects must not plan for pregnancy or oocyte donation from screening until 4 weeks after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include: * Barrier methods: Condom or barrier cap (diaphragm or cervical cap); * Intrauterine device (IUD) or intrauterine system (IUS); * Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner; * Other investigator-confirmed highly effective physical contraception. Exclusion Criteria: 1. Allergy to ruxolitinib cream; 2. Pregnant or lactating women; 3. Any condition deemed inappropriate for study participation by the investigator.